Actively Recruiting
Phase 2 Randomized Study of Melanotan II with Narrowband UV-B Phototherapy for Adults with Stable Nonsegmental Vitiligo
Led by Hudson Biotech · Updated on 2026-02-27
60
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
This trial focuses on adults with stable nonsegmental vitiligo, a condition where patches of skin lose pigment due to loss of melanocytes. The study evaluates whether adding the investigational drug Melanotan II MT-II to standard narrowband UV-B NB-UVB phototherapy can improve repigmentation. This randomized Phase 2 trial aims to assess the safety and early effectiveness of this combination treatment compared with placebo plus NB-UVB. Participants are randomly assigned to one of two groups one receiving Melanotan II alongside NB-UVB phototherapy and the other receiving placebo with NB-UVB. Treatments are given over a 24-week period following standardized schedules. The study includes digital photography, clinician assessments, and colorimetry to measure skin repigmentation. Safety is closely monitored through adverse event reporting, vital signs, and skin examinations, including checks for moles. A follow-up visit occurs four weeks after treatment ends to further assess safety. Throughout the study, participants undergo periodic evaluations including standardized imaging and scoring of vitiligo patches. Researchers measure changes in the Vitiligo Area Scoring Index VASI to gauge treatment impact. The study also collects safety data and monitors for any skin changes or side effects. Total participation spans the 24 weeks of treatment plus the follow-up visit, ensuring thorough observation of both effectiveness and safety.
CONDITIONS
Brief Title
Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo
Research Team
S
Seni S Lu, Phd
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here